Clinical trial
Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
NCT00128063 · International Antiviral Therapy Evaluation Center, Other · Completed
Key facts
| NCT number | NCT00128063 |
|---|---|
| Title | Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection |
| Official title | A Phase 1 & 2, Randomized Open-Label Study to Evaluate the Pharmacokinetics, Safety and Antiretroviral Activity of Succinylated Human Serum Albumin (Suc-HSA) in Treatment Naïve HIV-1 Infected Subjects |
| Lead sponsor | International Antiviral Therapy Evaluation Center, Other |
| Collaborators | University Medical Center Groningen Prothya Biosolutions Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | succinylated human serum albumin |
| Enrollment | 6 |
| Start date | Aug 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Aug 9, 2005 |
| Last update posted | Apr 24, 2007 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: